The Australasian Leukaemia and Lymphoma Group (ALLG) are proud to announce the official launch of the 2024 ALLG Research Report, highlighting our ongoing commitment to advancing clinical and translational blood cancer research.

This year’s comprehensive report showcases the extensive progress and outcomes achieved across the ALLG research network, with ALLG remaining at the forefront of haematology clinical trial research both locally and internationally.

The 2024 ALLG Research Report highlights our clinical trial portfolio over the past year, presenting key milestones, new scientific insights, and showcasing the power of collaboration in driving treatment innovation to improve patient outcomes.

 

 

Highlights of the 2024 Research Report

Blood cancers remain some of the most challenging diseases to treat. With no current prevention methods or screening programs, patients and their families often face uncertainty and limited treatment options. This is where ALLG’s work is critical.

Our clinical trials pursue high-impact, innovative blood cancer therapies that have the potential to change the standard of care and significantly improve survival and quality of life.

The 2024 ALLG Research Report offers a comprehensive look at our progress, achievements, and ongoing research initiatives. Inside, you’ll find:

• A detailed overview of our clinical trial portfolio
• Reports from leading researchers, including our Scientific Advisory Committee, Standing Member Committees, and Scientific Working Parties
• Milestones and strategic research developments from the past 12 months

The ALLG Research Report reflects the depth of our commitment, the strength of our collaborations, and the real-world impact of our clinical trials and is a testament to our mission-driven approach to advancing blood cancer treatment and care as we pursue Better treatments…Better lives.

 

Impact of ALLG’s Clinical Trial Portfolio

Since 1973, ALLG’s research has played a critical role in transforming the treatment landscape for blood cancers. Through our investigator-initiated clinical trials, more than 14,000 patients have gained access to the most advanced therapies available globally. Our work has not only improved treatment outcomes and quality of life for patients, but has shaped best-practice standards across Australia, New Zealand, and globally.

As we look to the future, we remain committed to collaboration, innovation, and putting patients at the centre of everything we do.

To read the full details of our research and clinical progress, download the 2024 ALLG Research Report.

Visit ALLG to learn more.